News

Amlodipine reduced vismodegib-induced muscle cramps


 

References

The calcium channel blocker amlodipine besylate was effective in reducing the number of muscle cramps caused by vismodegib, a basal cell carcinoma drug, according to a research letter from Dr. Mina Ally and her associates.

Patients who took amlodipine had the number of muscle cramps halved after 2 weeks of treatment, and this level was maintained for the 8-week medication regimen. No significant change in cramp severity, duration, or frequency of nighttime awakenings was seen. Side effects only appeared in too patients, with one reporting mild intermittent dizziness and another reporting grade 1 peripheral edema.

The control group saw a nonsignificant increase in cramp frequency, compared with the significant decrease in the amlodipine group. No change was seen in cramp severity, duration, or number of nighttime awakenings in the control group.

“Amlodipine may be effective in vismodegib-induced muscle cramps because it blocks voltage-gated calcium channels and inhibits the transport of extracellular calcium into muscle that is required for contraction,” the investigators noted.

Find the full research letter in JAMA Dermatology (doi:10.1001/jamadermatol.2015.1937).

lfranki@frontlinemedcom.com

Recommended Reading

High VTE recurrence risk persists for at least 3 years
MDedge Hematology and Oncology
Morbidities linger at least 20 years for young adult cancer survivors
MDedge Hematology and Oncology
Doxorubicin, radiation doses predict heart risk in lymphoma survivors
MDedge Hematology and Oncology
Guideline updated on hematopoietic colony-stimulating factors
MDedge Hematology and Oncology
Elevated IL-6 linked to complications after major abdominal surgery
MDedge Hematology and Oncology
CML patients die from comorbidities, not leukemia
MDedge Hematology and Oncology
ASCO: Include more older adults in cancer trials
MDedge Hematology and Oncology
Health care expenditures associated with depression in adults with cancer
MDedge Hematology and Oncology
A weekly speech and language therapy service for head and neck radiotherapy patients during treatment: maximizing accessibility and efficiency
MDedge Hematology and Oncology
Chemo lessens quality of life for end-stage patients with good performance status
MDedge Hematology and Oncology